And in the STEP 3 trial, participants who received semaglutide 2.4 mg plus intensive behavioral therapy lost an average of 16.0% of their bodyweight (as compared to 5.7% in the placebo group)
Kevin, an additional concern with GLP-1 drugs, and rapid weight loss in general, is muscle wasting , especially in people over 40
Talk with a medical weight management specialist to help determine the right approach for you one that is safe, sustainable and evidence-based
Most big pharma companies have at least one amylin in development, the most advanced of which is Novo Nordisks CagriSema, a dual amylin/GLP-1 agonist currently under FDA review
Because its compounded, its not evaluated for safety, efficacy, or quality by the FDA, but its a generic option, which means its more affordableeven without insurance
In an embryofetal development study in pregnant cynomolgus monkeys, subcutaneous doses of 0.015, 0.075, and 0.15 mg/kg twice weekly (0.5-, 3-, and 8-fold the MRHD) were administered throughout organogenesis, from Gestation Day 16 to 50